CN120549937A - 施用肌球蛋白抑制剂的方法 - Google Patents

施用肌球蛋白抑制剂的方法

Info

Publication number
CN120549937A
CN120549937A CN202510520246.XA CN202510520246A CN120549937A CN 120549937 A CN120549937 A CN 120549937A CN 202510520246 A CN202510520246 A CN 202510520246A CN 120549937 A CN120549937 A CN 120549937A
Authority
CN
China
Prior art keywords
dose
patient
mevalonate
treatment period
lvef
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510520246.XA
Other languages
English (en)
Chinese (zh)
Inventor
V·V·佩雷拉
S·梅拉利
A·塞纳特
M·张
D·塞托
J·劳克曼
M-L·帕皮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of CN120549937A publication Critical patent/CN120549937A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/06—Measuring blood flow
    • A61B8/065—Measuring blood flow to determine blood output from the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202510520246.XA 2022-04-26 2023-04-25 施用肌球蛋白抑制剂的方法 Pending CN120549937A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202263335028P 2022-04-26 2022-04-26
US202263335209P 2022-04-26 2022-04-26
US63/335,209 2022-04-26
US63/335,028 2022-04-26
US202263336254P 2022-04-28 2022-04-28
US63/336,254 2022-04-28
CN202380047093.0A CN119789856A (zh) 2022-04-26 2023-04-25 施用肌球蛋白抑制剂的方法
PCT/US2023/019710 WO2023211872A1 (en) 2022-04-26 2023-04-25 Methods of administering myosin inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202380047093.0A Division CN119789856A (zh) 2022-04-26 2023-04-25 施用肌球蛋白抑制剂的方法

Publications (1)

Publication Number Publication Date
CN120549937A true CN120549937A (zh) 2025-08-29

Family

ID=86558746

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510520246.XA Pending CN120549937A (zh) 2022-04-26 2023-04-25 施用肌球蛋白抑制剂的方法
CN202380047093.0A Pending CN119789856A (zh) 2022-04-26 2023-04-25 施用肌球蛋白抑制剂的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202380047093.0A Pending CN119789856A (zh) 2022-04-26 2023-04-25 施用肌球蛋白抑制剂的方法

Country Status (12)

Country Link
US (4) US20230338378A1 (https=)
EP (1) EP4514355A1 (https=)
JP (1) JP2025515491A (https=)
KR (1) KR20250016125A (https=)
CN (2) CN120549937A (https=)
AU (1) AU2023260472A1 (https=)
CA (1) CA3249509A1 (https=)
CL (1) CL2024003237A1 (https=)
IL (1) IL316204A (https=)
MX (1) MX2024013068A (https=)
TW (1) TW202400570A (https=)
WO (1) WO2023211872A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
WO2024182469A1 (en) * 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585885B2 (en) * 2012-12-10 2017-03-07 Kissei Pharmaceutical Co., Ltd. Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7447089B2 (ja) 2018-08-31 2024-03-11 サイトキネティックス， インコーポレイテッド 心筋サルコメア阻害剤
CN114945372A (zh) * 2019-11-10 2022-08-26 迈奥卡迪亚公司 用肌球蛋白调节剂的治疗方法
CA3190060A1 (en) * 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator

Also Published As

Publication number Publication date
US20250360132A1 (en) 2025-11-27
AU2023260472A1 (en) 2024-10-24
WO2023211872A1 (en) 2023-11-02
US20230338378A1 (en) 2023-10-26
KR20250016125A (ko) 2025-02-03
IL316204A (en) 2024-12-01
US20250288586A1 (en) 2025-09-18
JP2025515491A (ja) 2025-05-15
CA3249509A1 (en) 2023-11-02
US20240115568A1 (en) 2024-04-11
TW202400570A (zh) 2024-01-01
CL2024003237A1 (es) 2025-02-07
MX2024013068A (es) 2025-02-10
CN119789856A (zh) 2025-04-08
EP4514355A1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
CN120549937A (zh) 施用肌球蛋白抑制剂的方法
Writing Committee et al. 2022 ACC expert consensus decision pathway for integrating atherosclerotic cardiovascular disease and multimorbidity treatment: a framework for pragmatic, patient-centered care: a report of the American College of Cardiology Solution Set Oversight Committee
Goupil et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care
Legrain et al. A new multimodal geriatric discharge‐planning intervention to prevent emergency visits and rehospitalizations of older adults: the optimization of medication in AGE d multicenter randomized controlled trial
US20230360760A1 (en) Methods of regulating access to qsymia to mitigate potential drug-associated risks
Te Karu et al. Maori experiences and perceptions of gout and its treatment: a kaupapa Maori qualitative study
Hong et al. Grey–white matter ratio measured using early unenhanced brain computed tomography shows no correlation with neurological outcomes in patients undergoing targeted temperature management after cardiac arrest
Arora et al. Project ECHO: an effective means of increasing palliative care capacity
Jones et al. Characterization of glaucoma medication adherence in Kaiser Permanente Southern California
Wartna et al. Symptomatic treatment of pollen‐related allergic rhinoconjunctivitis in children: randomized controlled trial
Gutiérrez-Rojas et al. Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment
Deplanque et al. Drug repurposing: from the discovery of a useful pharmacological effect to making the treatment available to the patient
Shukkoor et al. Impact of clinical audit on adherence to the guidelines directed medical therapy in patients admitted with heart failure
Burford et al. Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction
Schulz et al. Impact of a medication management system on nursing home admission rate in a community-dwelling nursing home–eligible Medicaid population
Van Der Valk et al. Predicting intraocular pressure change before initiating therapy: timolol versus latanoprost
Klein et al. Models for drug individualization: patient to population level
Lewis et al. Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication
Hickman et al. Deprescribing of preventive medications in palliative care patients living with multiple long-term conditions in their final 12 months of life: A retrospective cohort Clinical Practice Research Datalink study
Larmer et al. Impact of pharmacist collaborative practice agreement on pharmacogenomic implementation for patients referred from geriatric medicine
García García et al. Frailty and Medication Appropriateness in Rural Adults: Proposing Interventions through Pharmacist–Physician Collaborative Efforts
Overholser et al. Patients with Cancer and Survivors
TIMing randomised controlled trial
Weatherald et al. Real-world persistence of selexipag for pulmonary arterial hypertension in Canada
Bui et al. Perioperative Medication Considerations for the Older Person

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination